Assists radiologists and emergency physicians in detecting fractures on DICOM musculoskeletal radiographs for adults and children aged 2 years or older, limited to the FDA-listed anatomic areas and standard views (ankle, clavicle, elbow, forearm, hip, humerus, knee, pelvis, shoulder, tibia/fibula, wrist, hand, and foot); it is an aided-diagnosis device and does not operate autonomously.
Evidence status: each field states its source quality, applicability, and review date. Research pending, information not established, and vendor documentation pending remain distinct outcomes.
Clinical details
What this tool is for
Start with the authorized purpose, then verify how it fits your service line and reading workflow.
Exact purpose
Assists radiologists and emergency physicians in detecting fractures on DICOM musculoskeletal radiographs for adults and children aged 2 years or older, limited to the FDA-listed anatomic areas and standard views (ankle, clavicle, elbow, forearm, hip, humerus, knee, pelvis, shoulder, tibia/fibula, wrist, hand, and foot); it is an aided-diagnosis device and does not operate autonomously.
DICOM radiographs from a DICOM Node or PACS, limited to the FDA-listed musculoskeletal study types and standard views: ankle, clavicle, elbow, forearm, hip, humerus, knee, pelvis, shoulder, tibia/fibula, wrist, hand, and foot.
Rayvolve outputs a prediction of potential fracture presence or absence and a processed image with bounding-box annotations localizing detected fractures; the initial image appears first and the processed image follows in the DICOM workflow, with annotations toggleable in the PACS/viewer.
Rayvolve does not replace medical doctors. Performance figures are endpoint- and population-specific; K240845 reports no new clinical study and references the predicate Rayvolve clinical-reader study. Local DICOM/PACS compatibility, commercial security, price, and service terms require qualification.
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
Use these fields to structure a vendor demo, security review, and implementation estimate.
Integration
The FDA packet describes current-edition DICOM interaction with existing DICOM Node servers such as PACS and clinical-grade viewers, with prediction output delivered as a processed DICOM image after the original.
FDA source
Exact FDA submission
Checked 2026-09-07
Specific interface versions, routing, viewer behavior, and local compatibility remain acceptance-test items.
The FDA comparison table contains a privacy characteristic, but the reviewed sources do not establish the current commercial security architecture, retention, access controls, audit, or incident-response terms.
Training and support
Vendor documentation pending
Vendor confirmation
Exact FDA submission
Checked 2026-09-07
The FDA packet says instructions for use are transmitted and used to train users; current onboarding, competency, and support commitments were not established.
Monitoring and change control
Vendor documentation pending
Vendor confirmation
Exact FDA submission
Checked 2026-09-07
Local acceptance testing, production monitoring, drift review, update control, and incident escalation remain to be qualified.
DICOM Node and PACS workflow
The exact FDA packet describes interaction with existing DICOM Node servers such as PACS and clinical-grade viewers, with the original image followed by the processed image containing fracture prediction and localization.
exact submission · checked 2026-09-07
Test representative identifiers, routing, image ordering, annotation toggles, and failure handling locally.
AZmed's current Rayvolve page describes local PACS/workflow integration in a radiology customer testimonial and presents Rayvolve as an AI second opinion for fracture detection.
product family · checked 2026-09-07
Vendor page and testimonial; it does not establish a specific connector, PACS version, SLA, or local deployment result.
The NIHR/NICE early value assessment table describes Rayvolve in the assessed NHS context as using DICOM radiographs and integrating into existing hospital radiology workflows through Wellbeing's AI Connect gateway. That assessment lists Rayvolve as adult-only for its evaluated context, whereas the exact K240845 FDA indication includes pediatric patients aged 2 years or older.
product family · checked 2026-09-07
Historical assessment context; do not use it to narrow or expand the exact FDA indication without the K240845 packet.
NICE HTG739 conditionally recommends Rayvolve for use in NHS urgent care while evidence is generated and calls for local disagreement protocols plus monitoring of accuracy, software failures, downstream referrals, treatment changes, implementation cost, subgroups, and postmarket surveillance.
product family · checked 2026-09-08
English NHS health-technology guidance; not exact K240845 pricing, reimbursement, or US adoption evidence.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The exact FDA submission reports standalone pediatric performance on 3,016 radiographs across all indicated study types and views: sensitivity 0.9611, specificity 0.8597, and ROC-AUC 0.9399. The submission states that no new clinical study was conducted for K240845 and references the predicate Rayvolve clinical reader study separately.
FDA source
Exact FDA submission
Checked 2026-09-07
The 3,016-case results are standalone pediatric testing; do not merge them with predicate adult clinical-reader results.
PopulationPediatric patients aged 2 years or older across the indicated musculoskeletal study types and views
Scopeexact submission
Tested versionRayvolve (K240845)
Samplen=3016
IndependenceIndependence not established
K240845
The FDA packet states that no clinical study was conducted in support of K240845; this standalone assessment supported inclusion of the pediatric population.
These are common procurement questions; unknown values remain visible until a source supports them.
Pricing and total cost
Vendor documentation pending
Vendor confirmation
Exact FDA submission
Checked 2026-09-07
No current exact-product price or contract terms were established from the reviewed public sources. The NICE assessment used a notional cost input, not a vendor quote.
Reimbursement and coding
Research pending
Needs research
Exact FDA submission
Checked 2026-08-31
Determine whether any product-specific CPT/HCPCS pathway exists and separate it from billing for the underlying imaging service.
No product-specific code
NICE HTG739 conditionally recommends Rayvolve for NHS use during a two-year evidence-generation period, subject to evidence-generation agreements and appropriate regulatory and DTAC approval; this is not a reimbursement determination.
NICE guidance for the NHS in England · England · Effective 2025-01-14
NICE's exploratory model uses GBP 1 per scan and says actual software, implementation, and postmarket costs are uncertain. This is not a vendor quote or US coverage evidence.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
Not established in reviewed sources
Reviewed sources checked
Exact FDA submission
Checked 2026-09-04
No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.
Buyer worksheet
Open questions to take to the vendor
Verify security and privacy controls: The FDA comparison table contains a privacy characteristic, but the reviewed sources do not establish the current commercial security architecture, retention, access controls, audit, or incident-response terms.
Verify training: The FDA packet says instructions for use are transmitted and used to train users; current onboarding, competency, and support commitments were not established.
Verify pricing and total cost: No current exact-product price or contract terms were established from the reviewed public sources. The NICE assessment used a notional cost input, not a vendor quote.
Verify reimbursement and coding relevance: Determine whether any product-specific CPT/HCPCS pathway exists and separate it from billing for the underlying imaging service.
Verify local validation and lifecycle monitoring: Local acceptance testing, production monitoring, drift review, update control, and incident escalation remain to be qualified.
Verify recalls and postmarket safety signals: No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-07Last searched
28Fields reviewed
10Source classes checked
9Screened PubMed leads
1Screened trial leads
0Unreviewed FDA recall leads
The stored evidence-candidates metadata and identifier lists were screened in order. This was metadata screening, not a full paper or ClinicalTrials.gov record review; no candidate abstract or full text is promoted here. The current discovery snapshot contains 9 PubMed and 1 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, health technology assessment, literature index, trial registry, pubmed, clinical trials, openfda device recall
Sources & history
How this profile was documented
Open the ledger for source dates, scope, and research-record updates.
View source ledger and history10 sources - 2 history items
Aids clinicians and radiologists reviewing 2D X-ray radiographs by detecting, localizing, and characterizing fractures across the FDA-listed appendicular, hip/pelvis, clavicle,...
FractureDetect (FX) is a computer-assisted detection and diagnosis (CAD) software device to assist clinicians in detecting fractures during the review of radiographs of the...
Opportunistically analyzes standard AP hip or pelvis radiographs in patients aged 50 years and older and issues a report when the estimated femoral-neck BMD is below a preset...
The Zebra HealthJOINT device is a software tool for 3D reconstruction of bones from a set of 2D radiographs. The device is intended for assisting clinicians in the preoperative...